TLR9 agonists also enhance the differentiation of B cells into antibody-secreting plasma cells and could potentially eradicate tumor cells through antibody dependent cellular cytotoxicity (ADCC) [19]–[21]. The gene discussed is TLR9; the disease is neoplasm.